Enterprise Value

92.31M

Cash

40.03M

Avg Qtr Burn

-9.639M

Short % of Float

9.46%

Insider Ownership

3.20%

Institutional Own.

23.62%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Iopofosine (CLR 131) Details
Cancer, Lymphoma, Waldenstrom macroglobulinemia

Phase 2b

Data readout

Iopofosine (CLR 131) Details
Cancer, Multiple myeloma, High Refractory Multiple Myeloma

Phase 2

Data readout

Iopofosine (CLR 131) Details
Cancer, B-cell lymphoma, Lymphoma

Phase 2

Update

Iopofosine (CLR 131) Details
B-cell lymphoma, B-cell malignancies, Lymphoma, Cancer, Pediatric Sarcomas, High-grade Glioma

Phase 1b

Data readout

Iopofosine (CLR 131) + EBRT Details
Head and neck cancer, Head and neck squamous cell carcinoma

Phase 1

Update